

CLAIMS

1. The use of an mGluR5 antagonist for the treatment of anxiety.
2. The use of a mGluR5 antagonist in the manufacture of a pharmaceutical composition for the treatment of anxiety.
3. A pharmaceutical composition incorporating as active agent a mGluR5 antagonist for use in the treatment of anxiety.
4. A method of treating anxiety in a subject in need of such treatment, comprising administration to such subject of a therapeutically effective amount of a mGluR5 antagonist.
5. The use of a mGluR5 antagonist for the treatment of pain.
6. The use of a mGluR5 antagonist in the manufacture of a pharmaceutical composition for the treatment of pain.
7. A pharmaceutical composition incorporating as active agent a mGluR5 antagonist, for use in the treatment of pain.
8. A method of treating pain in a subject in need of such treatment, comprising administration to such subject of a therapeutically effective amount of a mGluR5 antagonist.
9. The use of mGluR antagonist for the treatment of pain, whereby analgesic effect is achieved by interaction of said antagonist primarily or predominantly at peripheral mGluR receptors.
10. The use of a mGluR antagonist in the manufacture of a pharmaceutical composition for the treatment of pain by interaction of said antagonist primarily or predominantly at peripheral mGluR receptors

11. A pharmaceutical composition incorporating as active agent a mGluR antagonist, for use in the treatment of pain, whereby analgesic effect is achieved by interaction of said antagonist primarily or predominantly at peripheral mGluR receptors.
12. A method of treating pain in a subject in need of such treatment, comprising administration to such subject of a therapeutically effective amount of a mGluR antagonist, whereby analgesic effect is achieved by interaction of said antagonist primarily or predominantly at peripheral mGluR receptors.
13. A use, composition or method according to anyone of claims 9 to 12, whereby the mGluR antagonist is a specific mGluR5 antagonist.
14. A use, composition or method according to anyone of claims 9 to 12, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist, which does not substantially penetrate the CNS.
15. A use, composition or method according to anyone of claims 9 to 12, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist which does not substantially cross the blood-brain barrier.
16. A use, composition or method according to anyone of claims 9 to 12, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist in such a way that it does not substantially penetrate the CNS.
17. A use, composition or method according to anyone of claims 9 to 12, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist transdermally.
18. A use, composition or method according to anyone of claims 9 to 17, whereby the condition to be treated is inflammatory or neuropathic pain.